Seoul Pharma Co., Ltd
Financials
Valuation Metrics
Seoul Pharma Co., Ltd's Market Cap is ₩196B. At end of 2025 it was ₩359B. Ranked #2279 of 2,405 in KR market (top 95%), #1515 of 1,627 on KOSDAQ (top 93%), #225 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 19.62B KRW | KR#2,279/2,405 Sec#225/231 |
| Revenue | 51.08B KRW | KR#1,770/2,405 Sec#120/231 |
| Net Income | 1.74B KRW | KR#1,432/2,405 Sec#98/231 |
| Total Assets | 68.24B KRW | KR#2,024/2,405 Sec#170/231 |
| Net Assets | 40.54B KRW | KR#2,031/2,405 Sec#180/231 |
| Employees | 176 | KR#1,183/2,405 Sec#97/231 |
| Value | ||
| P/E | 11.28x | KR#929/2,405 Sec#49/231 |
| P/B | 0.48x | KR#828/2,405 Sec#34/231 |
| P/S | 0.38x | KR#793/2,405 Sec#28/231 |
| FCF Yield | 5.22% | KR#859/2,405 Sec#48/231 |
| Profitability | ||
| ROE | 4.29% | KR#1,181/2,405 Sec#82/231 |
| ROA | 2.55% | KR#1,114/2,405 Sec#83/231 |
| Op. Margin | -1.53% | KR#1,711/2,405 Sec#116/231 |
| Revenue Growth | -2.14% | KR#1,628/2,405 Sec#159/231 |
| Financial Health | ||
| Debt Ratio | 68.32% | KR#1,193/2,405 Sec#145/231 |
| Total Debt | 13.00B KRW | KR#1,531/2,405 Sec#134/231 |
| FCF | 1.02B KRW | KR#1,143/2,405 Sec#86/231 |
| Cash | 16.82B KRW | KR#1,363/2,405 Sec#107/231 |
| Current Ratio | 1.45x | KR#1,238/2,405 Sec#133/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -45.36% | KR#1,841/2,405 Sec#156/231 |
| 1M Return | -13.16% | KR#1,429/2,405 Sec#144/231 |
| From 52W High | -49.15% | KR#1,140/2,405 Sec#91/231 |
| 1Y MDD | -46.82% | KR#814/2,405 Sec#63/231 |
| Trading | ||
| Volume | 3,989 shares | KR#2,154/2,405 Sec#218/231 |
| Trading Value | 6.7M KRW | KR#2,290/2,405 Sec#228/231 |
| Foreign Own. | 2.17% | KR#1,564/2,405 Sec#149/231 |
| Per Share | ||
| EPS | 149 KRW | KR#1,360/2,405 Sec#91/231 |
| BPS | 3,477 KRW | KR#1,769/2,405 Sec#131/231 |
Company Info
Established in 1985 and listed on KOSDAQ in 2000, this pharmaceutical company produces drugs such as antihypertensive Ator, stroke treatment Plavel, and obesity treatment Weltmin. It leverages SmartFilm® Technology for oral disintegrating film manufacturing, supplying products to partners like Pfizer Korea. The company is preparing new and generic drugs for chronic diseases like hyperlipidemia, gastroesophageal reflux disease, and diabetes to expand market share, with its new Osong plant establishing a foundation for global expansion. Seoul Pharma is headquartered in Cheongju-si, Chungcheongbuk-do.